Alunbrig (brigatinib)

pCPA File Number: 21467

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor

Sponsor/Manufacturer:

Takeda Canada Inc.

CADTH Project Number:

PC0230-000

pCPA Engagement Letter Issued:

2021-10-29

Negotiation Process Concluded:

2021-12-16